Cargando…
A large randomized clinical trial is necessary to establish the role of camrelizumab in hepatocellular carcinoma
Autores principales: | Ravindran, Nishal, Thuluvath, Paul J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7607078/ https://www.ncbi.nlm.nih.gov/pubmed/33178785 http://dx.doi.org/10.21037/atm-2020-71 |
Ejemplares similares
-
Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma
por: Rakké, Yannick Sebastiaan, et al.
Publicado: (2020) -
Gastrointestinal and Liver Manifestations of COVID-19
por: Agarwal, Amol, et al.
Publicado: (2020) -
Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022) -
What GI Physicians Need to Know During COVID-19 Pandemic
por: Thuluvath, Paul J., et al.
Publicado: (2020) -
Are Gastrointestinal Symptoms Specific for Coronavirus 2019 Infection? A Prospective Case-Control Study From the United States
por: Chen, Alan, et al.
Publicado: (2020)